Actinic Keratosis Treatment Market to Hit Around USD 11.03 Bn By 2033
The global actinic keratosis treatment market size was exhibited at USD 6.90 billion in 2023 and is projected to hit around USD 11.03 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024 to 2033.
Download Free Sample Copy for Better Understanding@ https://www.novaoneadvisor.com/report/sample/7371
Key Takeaways:
The market is anticipated to witness growth opportunities owing to factors such as the rising prevalence of Actinic Keratosis (AK) and the wide presence and easy availability of generic drugs for its treatment. Moreover, the market is driven by increasing awareness about actinic keratosis and various strategic initiatives undertaken by industry players. Increasing consumer awareness regarding dermatological diseases, such as actinic keratosis, is a major growth booster for the market.
Heightened knowledge about diagnostics and treatment strategies for this disease has driven the widespread adoption of actinic keratosis medications. Several field-directed treatments including 5-fluorouracil, ingenol mebutate, diclofenac, and imiquimod are poised to witness greater market expansion over the next few years. Although the products share similar efficacies, the cosmetic outcomes and adverse effects might differ. Photodynamic therapy was observed to be better than cryotherapy in terms of cosmetic outcomes. Moreover, the easy accessibility and availability of treatments for actinic keratosis are expected to be a significant growth factor for this market.
The prevalence of actinic keratosis is one of the major market drivers. According to an article published by News-Medical.net, an AZoNetwork site in 2019, the prevalence of actinic keratosis is 37% to 55% in Australian adults aged over 40. This is linked to high UV exposure in the Australian population with relatively fair skin. Outdoor sports are very popular in Australia and as a result, they tend to spend their maximum time in the sun. The article further suggests that men are more prone to actinic keratosis than women, but it is also linked to other risk factors such as time spent outside in the sun and overall exposure to the sun. In addition, the overall prevalence of actinic keratosis in the U.S. and the UK is estimated to be 26.5% in males & 10.2% in females, and 6.15% in males and 6% in females, respectively.
Segments Insights:
Therapy Insights
Based on therapy, the market is segmented into topical, surgery, and photodynamic therapy. Surgery held the largest revenue share of 66.0% in 2023. The surgery segment is likely to maintain its dominance during the forecast period owing to higher penetration of cryotherapy for the treatment of actinic keratosis, where actinic keratosis is removed by the application of liquid nitrogen to freeze the affected area causing blistering or peeling. Apart from cryotherapy, curettage, laser therapy, and photodynamic therapy are other types of surgeries.
The photodynamic therapy (PDT) segment is expected to grow at the fastest CAGR of 7.4% over the forecast period from 2024 to 2033. Rising usage of non-invasive therapies and greater efficiency of PDT (photodynamic therapy) in comparison with cryotherapy are factors anticipated to foster the segment’s growth. Photodynamic therapy is a preferred treatment for patients with actinic keratosis relapse.
Drug Class Insights
Based on drug class, the market is segmented into nucleoside metabolic inhibitors, NSAIDs, immune response modifiers, photoenhancers, and others. Nucleoside metabolic inhibitors held the largest revenue share of 32.4% in 2023. The growth is attributed to the strong commercial performance of Efudex, Carac, and Fluoroplex. Moreover, the increased awareness regarding actinic keratosis treatment and diagnosis has fueled the growth of the segment.
The growth of the nucleoside metabolic inhibitors segment is also augmented by various strategic initiatives taken up by the industry players. For instance, in June 2020, Hill Dermaceuticals, Inc., a leader in dermatological products, announced that its product, Tolak (Fluorouracil) 4% Cream, has been successfully registered in 13 countries of Europe including the UK, France, Belgium, and Italy.
End-use Insights
Based on end-use, the market is segmented into hospitals, private clinics, homecare, and others. The hospitals segment held the largest share of 30.4% in 2023. This is attributed to factors such as treatment rate accessibility, availability of healthcare facilities, and rising photodynamic therapy procedures performed in hospitals. Several prescription medicines are available that are used in performing photodynamic therapy. LEVULAN and KERASTICK are prescription medicines manufactured by DUSA Pharmaceuticals, Inc. and are used on skin with blue light treatment (PDT) for the management of minimally to moderately thick actinic keratosis of the scalp, upper arms, and face.
The homecare segment is expected to grow at the fastest CAGR of 5.2% during the forecast period owing to the rising adoption of topical products, patient convenience factors, availability of OTC products, and the increasing launch of products for topical use. Moreover, the homecare segment has witnessed an increased demand due to the rising availability of topical products. For instance, Tolak 4% cream manufactured by Hill Pharmaceuticals is a topical prescription medicine used to treat skin lesions of actinic keratosis, and Zyclara, manufactured by Bausch Health Companies Inc., is an imiquimod cream used for the topical treatment of actinic keratosis.
Regional Insights
North America dominated the market with the largest revenue share of 45.0% in 2023 and is anticipated to maintain its dominance over the forecast period. This can be attributed to the rising prevalence of actinic keratosis, favorable government initiatives, rising consumer awareness, improvements in healthcare infrastructures, and ongoing technological advancements. The presence of key players is also one of the key factors responsible for the regional growth.
In addition, favorable government initiatives and reimbursement policies are expected to boost industry growth. According to the information updated by Cleveland Clinic in December 2020, 58 million Americans are diagnosed with single as well as multiple actinic keratosis spots. Furthermore, according to the Canadian Skin Cancer Foundation, 60% of Canadians above the age of 40 have at least one actinic keratosis spot on their skin.
In June 2023, Biofrontera Inc. announced its The Sun Bus sponsorship. It’s a mobile clinic and classroom offering public education and free skin cancer screening to communities in the U.S. Biofrontera is committed to enhancing AK lesions treatment that are premalignant, however, if left untreated, may lead to squamous cell carcinoma.
Asia Pacific is expected to grow at the fastest CAGR of 5.6% during the forecast period. An increase in the adoption of treatment, rising consumers’ disposable income, and high disease prevalence in some nations, such as Australia and New Zealand, are some of the key factors driving the regional growth. According to the information published by the International Agency for Research on Cancer (IARC) in 2020, a subsidiary of the World Health Organization (WHO), the age-standardized mortality rate (ASR) world of Asian countries due to melanoma of skin is 9.3, 3.8, and 1.5 for Israel, Georgia, and Turkey, respectively. China’s ASR was 0.31, India’s 0.24, and Japan’s 0.42 in the same year.
Some of the prominent players in the Actinic keratosis treatment market include:
Almirall S.A.
LEO Pharma A/S
Sun Pharmaceutical Industries Ltd.
领英推荐
Novartis AG
GALDERMA
Ortho Dermatologics (Bausch Health Companies Inc.)
BIOFRONTERA AG
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global actinic keratosis treatment market.
Therapy
Drug Class
End-use
By Region
Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/7371 ?
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333
About US
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
Connect with Us
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
·??????? IND Address: 2nd Floor,Shreeleela Plaza, Baner Road, Pune, Maharashtra - 411045
·??????? Call: USA - +1 650 460 3308 | IND - +91 8793322019 | Europe +442080772818
·??????? [email protected]